BioVersys Initiates BV100 Phase 3 Clinical Trial, Raises CHF 76.7 Million in IPO
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 hour ago0mins
- Phase 3 Trial Launch: BioVersys initiated the BV100 Phase 3 clinical trial in December 2025, with preliminary data expected in H2 2027, marking a significant advancement in the fight against drug-resistant bacterial infections.
- Successful IPO Financing: The company completed its IPO on the SIX Swiss Exchange in February 2025, raising CHF 76.7 million, which significantly extends its cash runway to 2028, supporting the BV100 Phase 3 trial and other R&D projects.
- Global Collaboration Expansion: BioVersys entered into a global research collaboration with Japanese pharmaceutical company Shionogi to advance the BV500 program, which aims to provide new treatment options for approximately 250,000 patients affected by NTM infections annually, enhancing the company's market competitiveness.
- Diversified Clinical Trials: The Phase 2b trial for BV100 received funding from Wellcome and is expected to start in H1 2026, aiming to provide real-world evidence that enhances the company's clinical practice capabilities in high-resistance environments.
BVS.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BVS
Wall Street analysts forecast BVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BVS is USD with a low forecast of 14.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.190
Low
14.00
Averages
High
15.00
Current: 7.190
Low
14.00
Averages
High
15.00
Cantor Fitzgerald
Ross Osborn
Overweight
initiated
$12
2025-07-07
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$12
2025-07-07
initiated
Overweight
Reason
Cantor Fitzgerald analyst Ross Osborn initiated coverage of Bioventus with an Overweight rating and $12 price target.
Canaccord Genuity
Caitlin Cronin
Strong Buy
Maintains
$15
2025-03-17
Reason
Canaccord Genuity
Caitlin Cronin
Price Target
$15
2025-03-17
Maintains
Strong Buy
Reason
JP Morgan
Robbie Marcus
Sell
to
Hold
Upgrades
$12 → $13
2024-12-17
Reason
JP Morgan
Robbie Marcus
Price Target
$12 → $13
2024-12-17
Upgrades
Sell
to
Hold
Reason
See All Ratings
About BVS
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What fiduciary duties are being investigated at Bioventus Inc?
How can shareholder involvement improve Bioventus's corporate governance policies?
What are the potential outcomes of the shareholder rights investigation for Bioventus?
How might Bioventus's management effectiveness change after legal reforms?